Orion Oyj Logo

Orion Oyj

Develops and manufactures human/vet pharma, APIs, and generics for global markets.

ORNAV | HE

Overview

Corporate Details

ISIN(s):
FI0009014377 (+1 more)
LEI:
74370029VAHCXDR7B745
Country:
Finland
Address:
Orionintie 1, FI-02200 ESPOO
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Orion Oyj is a globally operating Finnish pharmaceutical company that develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs). With a history of over a century, the company focuses on 'building well-being' by translating scientific research into novel therapies and treatments. Orion's research and development efforts are primarily concentrated on specific therapeutic areas, including oncology and pain management. In addition to its portfolio of proprietary drugs, the company also produces generic products and self-care items. Its subsidiary, Fermion, is a key manufacturer of APIs for both Orion and external customers worldwide. Orion also engages in contract manufacturing and the development of diagnostic tests.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-28 11:00
Orion-konsernin osavuosikatsaus tammi-syyskuu 2025
Finnish 22.8 KB
2025-10-28 11:00
Orion Group Interim Report January-September 2025
English 22.5 KB
2025-10-24 08:00
49 164 kpl Orion Oyj:n A-osaketta muunnettu B-osakkeiksi
Finnish 2.7 KB
2025-10-24 08:00
49,164 Orion Corporation A shares converted into B shares
English 2.8 KB
2025-09-30 08:00
Orion Oyj: Arvopaperimarkkinalain 9. luvun 10. pykälän mukainen ilmoitus (Black…
Finnish 5.6 KB
2025-09-30 08:00
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Mark…
English 5.7 KB
2025-09-26 15:30
Orion Oyj: Arvopaperimarkkinalain 9. luvun 10. pykälän mukainen ilmoitus (Black…
Finnish 5.6 KB
2025-09-26 15:30
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Mark…
English 5.7 KB
2025-09-19 08:00
80 802 kpl Orion Oyj:n A-osaketta muunnettu B-osakkeiksi
Finnish 2.7 KB
2025-09-19 08:00
80,802 Orion Corporation A shares converted into B shares
English 2.8 KB
2025-08-20 08:00
337 000 kpl Orion Oyj:n A-osaketta muunnettu B-osakkeiksi
Finnish 2.7 KB
2025-08-20 08:00
337,000 Orion Corporation A shares converted into B shares
English 2.8 KB
2025-08-08 08:30
Orion Oyj: Johtohenkilöiden liiketoimet - Juhani Kankaanpää
Finnish 4.9 KB
2025-08-08 08:30
Orion Corporation: Managers' transactions - Juhani Kankaanpää
English 4.8 KB
2025-08-04 15:10
Orion Oyj: Johtohenkilöiden liiketoimet - Satu Ahomäki
Finnish 3.5 KB

Automate Your Workflow. Get a real-time feed of all Orion Oyj filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Orion Oyj

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Orion Oyj via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Developing targeted AAV genetic medicines for large market eye, lung, and heart diseases.
United States of America
FDMT
4SC AG Logo
Developing small-molecule epigenetic drugs for high-need cancer indications.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops medicines for tropical diseases, including ARAKODA for malaria prevention.
United States of America
SXTP
89bio, Inc. Logo
Developing therapies for liver and cardiometabolic diseases like MASH and SHTG.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Developing oral drugs to suppress appetite for obesity and rare metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Develops medical devices, diagnostics, nutritionals, and pharmaceuticals for global health.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharma firm creating medicines for immunology, oncology, and neuroscience.
United States of America
ABBV
AbCellera Biologics Inc. Logo
An AI-powered platform that discovers and develops antibody therapeutics for pharma partners.
United States of America
ABCL
Develops antibody therapeutics and CAR-T for oncology and provides CRO services.
South Korea
174900

Talk to a Data Expert

Have a question? We'll get back to you promptly.